Abstract
The objective of this Special Report is to estimate the medical cost per life-year gained from increased utilization of HIV drugs by estimating the impact of increased drug utilization on the life expectancy and drug and hospital expenditure of HIV/AIDS patients, using aggregate (US national-level) data for the period 1982–2001.
Acknowledgement
The research was supported by Abbott Laboratories (IL, USA). The publication of study results was not contingent on the sponsor’s approval or censorship of the manuscript.